HopeStage
Back to all studies
WithdrawnNCT00743847

A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia

Medication studyAges 18–55
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMarch 2009
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Not clearly listed
Age range
From 18 Years to 55 Years
Official registry ID
NCT00743847
Official title
Show the full official title

A Phase 2 6-Week, Double-Blind, Placebo-Controlled, Multicenter Trial Of Varenicline Tartrate (CP-526,555) For Cognitive Impairment In Subjects With Schizophrenia

Recruitment & locations

Withdrawn

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer.

Does this study involve medication?

Yes. The study involves medication, including placebo and varenicline.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies